The discovery by structure-based and combinatorial methods of new RNA-bindi
ng drugs presents great opportunities for pharmacological development again
st drug-resistant bacterial and viral pathogens. A handful of recent RNA st
ructures and more numerous studies of the interaction of combinatorial libr
aries and oligomeric RNA-binding compounds are providing the foundation for
effective RNA-targeted drug discovery programs.